TLC518

TLC518 is an investigational drug candidate developed by TLC BioSciences (Taiwan Liposome Company) for the treatment of metabolic and immune disorders. The asset utilizes TLC's proprietary lipid-based drug delivery technology, such as the BioSeizer® or NanoX™ platforms, which are designed to encapsulate therapeutic agents within lipid membranes to achieve sustained release or enhanced targeting. While the specific active pharmaceutical ingredient and biological target have not been publicly disclosed by the developer, the program aims to address unmet needs in chronic metabolic and immunological conditions by optimizing the delivery and pharmacokinetic profile of the therapeutic agent. TLC518 is part of a broader pipeline that leverages liposomal formulations to improve the therapeutic index of established or novel drugs.